Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos de neuro-psiquiatria (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2009000100016 |
Resumo: | We evaluated the safety and effectiveness of botulinum toxin A (BoNT/A) in the treatment of spasticity in 20 children with spastic diplegic cerebral palsy (CP). All the patients received injections in the gastrocnemius and soleus, and 15 received injections in the adductors. The total dose varied from 70 to 140 U (99.75±16.26 U), or 7.45±2.06 U/kg per patient. The treatment improved the patients' walking and gait pattern significantly. There was also a significant alteration in the heel-ground distance and increased motion of the ankle joint. These structural changes in the feet were sustained until the end of the follow-up, although the same was not observed for the functional parameters. Three patients complained of weakness in the lower limbs. In conclusion, BoNT/A is safe and effective when used in a single session of injections and produces a sustained structural modification of the lower limbs. However, functional changes are temporary and are only observed during the peak effect of the drug. |
id |
ABNEURO-1_522edd5d45f28b22f0903e6f5bfd5667 |
---|---|
oai_identifier_str |
oai:scielo:S0004-282X2009000100016 |
network_acronym_str |
ABNEURO-1 |
network_name_str |
Arquivos de neuro-psiquiatria (Online) |
repository_id_str |
|
spelling |
Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsycerebral palsybotulinum toxinspasticityWe evaluated the safety and effectiveness of botulinum toxin A (BoNT/A) in the treatment of spasticity in 20 children with spastic diplegic cerebral palsy (CP). All the patients received injections in the gastrocnemius and soleus, and 15 received injections in the adductors. The total dose varied from 70 to 140 U (99.75±16.26 U), or 7.45±2.06 U/kg per patient. The treatment improved the patients' walking and gait pattern significantly. There was also a significant alteration in the heel-ground distance and increased motion of the ankle joint. These structural changes in the feet were sustained until the end of the follow-up, although the same was not observed for the functional parameters. Three patients complained of weakness in the lower limbs. In conclusion, BoNT/A is safe and effective when used in a single session of injections and produces a sustained structural modification of the lower limbs. However, functional changes are temporary and are only observed during the peak effect of the drug.Academia Brasileira de Neurologia - ABNEURO2009-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2009000100016Arquivos de Neuro-Psiquiatria v.67 n.1 2009reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/S0004-282X2009000100016info:eu-repo/semantics/openAccessCamargo,Carlos Henrique F.Teive,Hélio A.G.Zonta,MariseSilva,Gilmar C.Oliveira,Marcelo R.Roriz,Maurício M.Brandi,Ivar V.Becker,NilsonScola,Rosana HermíniaWerneck,Lineu Césareng2009-03-24T00:00:00Zoai:scielo:S0004-282X2009000100016Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2009-03-24T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse |
dc.title.none.fl_str_mv |
Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy |
title |
Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy |
spellingShingle |
Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy Camargo,Carlos Henrique F. cerebral palsy botulinum toxin spasticity |
title_short |
Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy |
title_full |
Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy |
title_fullStr |
Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy |
title_full_unstemmed |
Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy |
title_sort |
Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy |
author |
Camargo,Carlos Henrique F. |
author_facet |
Camargo,Carlos Henrique F. Teive,Hélio A.G. Zonta,Marise Silva,Gilmar C. Oliveira,Marcelo R. Roriz,Maurício M. Brandi,Ivar V. Becker,Nilson Scola,Rosana Hermínia Werneck,Lineu César |
author_role |
author |
author2 |
Teive,Hélio A.G. Zonta,Marise Silva,Gilmar C. Oliveira,Marcelo R. Roriz,Maurício M. Brandi,Ivar V. Becker,Nilson Scola,Rosana Hermínia Werneck,Lineu César |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Camargo,Carlos Henrique F. Teive,Hélio A.G. Zonta,Marise Silva,Gilmar C. Oliveira,Marcelo R. Roriz,Maurício M. Brandi,Ivar V. Becker,Nilson Scola,Rosana Hermínia Werneck,Lineu César |
dc.subject.por.fl_str_mv |
cerebral palsy botulinum toxin spasticity |
topic |
cerebral palsy botulinum toxin spasticity |
description |
We evaluated the safety and effectiveness of botulinum toxin A (BoNT/A) in the treatment of spasticity in 20 children with spastic diplegic cerebral palsy (CP). All the patients received injections in the gastrocnemius and soleus, and 15 received injections in the adductors. The total dose varied from 70 to 140 U (99.75±16.26 U), or 7.45±2.06 U/kg per patient. The treatment improved the patients' walking and gait pattern significantly. There was also a significant alteration in the heel-ground distance and increased motion of the ankle joint. These structural changes in the feet were sustained until the end of the follow-up, although the same was not observed for the functional parameters. Three patients complained of weakness in the lower limbs. In conclusion, BoNT/A is safe and effective when used in a single session of injections and produces a sustained structural modification of the lower limbs. However, functional changes are temporary and are only observed during the peak effect of the drug. |
publishDate |
2009 |
dc.date.none.fl_str_mv |
2009-03-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2009000100016 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2009000100016 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0004-282X2009000100016 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Academia Brasileira de Neurologia - ABNEURO |
publisher.none.fl_str_mv |
Academia Brasileira de Neurologia - ABNEURO |
dc.source.none.fl_str_mv |
Arquivos de Neuro-Psiquiatria v.67 n.1 2009 reponame:Arquivos de neuro-psiquiatria (Online) instname:Academia Brasileira de Neurologia instacron:ABNEURO |
instname_str |
Academia Brasileira de Neurologia |
instacron_str |
ABNEURO |
institution |
ABNEURO |
reponame_str |
Arquivos de neuro-psiquiatria (Online) |
collection |
Arquivos de neuro-psiquiatria (Online) |
repository.name.fl_str_mv |
Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia |
repository.mail.fl_str_mv |
||revista.arquivos@abneuro.org |
_version_ |
1754212765366484992 |